How long should you stay on 5mg Mounjaro before moving up?

What the SURMOUNT trial data tells us about the titration period

The SURMOUNT-1 trial, published in the New England Journal of Medicine and the basis for tirzepatide's weight-management licence, used a structured four-weekly titration schedule: each dose level was held for a minimum of four weeks before the next step. That schedule existed not because four weeks is a magic number for efficacy, but because it gave participants time to adapt to each dose before adding more. Nausea, the most commonly reported side effect in the trial, tended to peak shortly after a dose change and then ease, meaning the four-week window is essentially a tolerance-building buffer as much as it is a therapeutic one.

In the real world, prescribers apply that schedule with flexibility. If gastrointestinal symptoms are still noticeable going into week four, staying at 5mg for an additional four weeks is a recognised and sensible option. The NICE technology appraisal for tirzepatide (TA1026) focuses on outcomes over the full treatment course rather than prescribing a rigid week-by-week timetable, which reinforces that clinical judgement governs pace. You can read more about what the 5mg dose involves on our Mounjaro 5mg overview page.

One straightforward habit worth building at this stage: weigh yourself once a week, at the same time of day and on the same scales, and note it somewhere. That single data point gives your prescriber something concrete to work with when reviewing whether to move you on.

How long can you stay on 5mg Mounjaro, is there a ceiling?

There is no absolute upper time limit for staying at 5mg, but there is context worth understanding. The 5mg dose is part of a titration pathway that leads to higher maintenance doses, and the clinical evidence for substantial, sustained weight reduction is strongest at the higher end of the range, particularly 10mg and 15mg. Staying at 5mg indefinitely because it feels comfortable would mean missing the therapeutic benefit that the licence is based on.

That said, 5mg is not merely a stepping stone. For some patients, side effects at 7.5mg or above are significant enough that the prescriber and patient agree to stay lower for a longer period, or to move more slowly through the schedule. This is a legitimate clinical choice, not a failure. The question of how long you stay on 5mg Mounjaro is therefore really two questions: are you tolerating this dose well enough to move up, and is your weight trajectory suggesting the current dose is sufficient for now? Your prescriber is the right person to answer both.

If you're curious how the pace of titration shifts at other points in the schedule, our page on staying on 15mg covers the maintenance end of the picture, and our guide to how long to stay on 2.5mg Mounjaro covers where the journey starts, with our page on how long you stay on 2.5mg Mounjaro exploring that opening phase in more detail.

Side effects at 5mg and what they mean for your timeline

GI side effects are the primary reason prescribers slow titration down. Nausea, loose stools, reduced appetite, and occasional vomiting are common in the early weeks, they're one of the most consistent findings across tirzepatide trials, and they typically ease as the body adjusts. If they haven't eased by week three or four at 5mg, your prescriber may recommend staying put rather than adding the next increment.

This is worth saying plainly: experiencing side effects at 5mg is not a sign that the medicine is wrong for you. It usually means the titration is doing exactly what it should, introducing a physiological change gradually. The NHS guidance on tirzepatide notes that side effects are generally most noticeable after a dose change and tend to improve. Pushing through an increase before your system has settled tends to make things harder, not faster. Patience at this stage is, counterintuitively, the more efficient route.

One thing to keep in mind: if you experience severe, persistent stomach pain that spreads to the back, that warrants prompt medical attention regardless of where you are in the titration schedule. Acute pancreatitis is a recognised but uncommon risk with GLP-1 medicines; the MHRA highlighted it in their January 2026 Drug Safety Update and it should not be waited out at home. You can read about side effect patterns more broadly on our Mounjaro treatment page.

How the decision to move up is made at nume

At nume, every repeat order triggers a clinical review. A prescriber, not an automated system, reads your update before any treatment is dispensed. That review specifically considers whether you're ready to move to the next dose or whether staying at 5mg for another cycle is the right call. There's no pressure in either direction, the aim is the right clinical outcome, not the fastest one.

Mounjaro is a prescription-only medicine. That means the titration schedule is not self-directed. If you've been reading about how long do you stay on 5mg Mounjaro and wondering whether you can simply extend or accelerate your dose, the answer is that those decisions belong with your prescriber. Our clinical team is available seven days a week for aftercare questions, and there's no additional charge for that support. For a broader look at what to expect across the full treatment journey, our weight-loss treatment overview sets out the wider context. Pricing information, if that's on your mind, is on the Mounjaro cost page.